Membranous Nephropathy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of MN for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s MN forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MN over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following MN patient populations:
- Diagnosed incidence of MN.
- Diagnosed prevalence of MN.
Table of contents
- Membranous Nephropathy - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of membranous nephropathy)
- Diagnosed incident cases of membranous nephropathy
- Diagnosed lifetime prevalent cases of membranous nephropathy
- Diagnosed drug-treated prevalent cases of membranous nephropathy
- Risk / protective factors applied to disease forecast models
- Reference Materials
